For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
9
views
0
references
 Top references
cited by
12
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      563
      similar
       All similar
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims: To analyse the correlation between serum human beta-defensin-2 (hBD-2) levels and response to JAK inhibitor in psoriasis. Methods: We evaluated the psoriasis area and severity index (PASI) and serum hBD-2 levels of 18 psoriasis patients randomized to receive placebo or tofacitinib 5 or 10 mg b.i.d. at baseline, week 8, and week 16. Serum hBD-2 levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: The PASI achieved a dramatic reduction after tofacitinib 5 or 10 mg b.i.d. treatment for 16 weeks ( p < 0.05). Serum hBD-2 levels significantly decreased in patients treated with tofacitinib 10 mg b.i.d. compared with baseline and the placebo-treated patients ( p < 0.05). A significant correlation was found between hBD-2 levels and PASI ( r = 0.52, p < 0.01). A serum hBD-2 level of 1,255.45 pg/mL was a cut-off between mild and moderate-to-severe psoriasis in ROC analysis. Conclusions: Serum hBD-2 level might be a possible biomarker for monitoring psoriasis treatment response and differentiating mild from moderate-to-severe psoriasis.

          Related collections

          Author and article information

          Journal
          Journal ID (publisher-id): DRM
          Journal ID (nlm-ta): Dermatology
          Journal ID (doi): 10.1159/issn.1018-8665
          Title: Dermatology
          Publisher: S. Karger AG
          ISSN (Print): 1018-8665
          ISSN (Electronic): 1421-9832
          Publication date Subscription-year: 2017
          Publication date (Print): October 2017
          Publication date (Electronic): 28 June 2017
          Volume: 233
          Issue: 2-3
          Pages: 164-169
          Affiliations
          aDepartment of Dermatology and Venereology, Peking University First Hospital, and bDepartment of Dermatology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China
          Author notes
          *Yi Zhao, Department of Dermatology, Beijing Tsinghua Changgung Hospital, Tsinghua University, No. 168 Litang Road, Changping District, Beijing 102218 (China), E-Mail zhaoyi@btch.edu.cn, Xixue Chen, Department of Dermatology and Venereology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034 (China), E-Mail xixue_chen@163.com
          Article
          Publisher ID: 475809 Other ID: Dermatology 2017;233:164-169
          DOI: 10.1159/000475809
          PubMed ID: 28654918
          SO-VID: a7e27d04-7e1f-4100-8662-2f6965c4bcea
          Copyright © © 2017 S. Karger AG, Basel
          License:

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Date received : 14 October 2016
          Date accepted : 18 April 2017
          Page count
          Figures: 5, Tables: 1, References: 17, Pages: 6
          Categories
          Subject: Original Paper

          ScienceOpen disciplines: Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
          Keywords: Psoriasis,Tofacitinib,Human beta-defensin-2,Biomarker
          Data availability:
          ScienceOpen disciplines: Oncology & Radiotherapy, Pathology, Surgery, Dermatology, Pharmacology & Pharmaceutical medicine
          Keywords: Psoriasis, Tofacitinib, Human beta-defensin-2, Biomarker

          Comments

          Comment on this article

          scite_

          Similar content563

          See all similar

          Cited by12

          See all cited by